Hearology®
Research

Childhood deafness gene therapy trial passes safety check

Sensorion’s SENS-501 trial for OTOF-related infant deafness clears a safety review, with early hearing responses. Experts urge cautious optimism.

Written by
HearologyThe Hearology team
Published29 January 2026
Updated17 November 2026
Read time3 min
The logo for Sensorion, featuring the brand name in a lowercase, dark blue sans-serif font. To the left of the text is a stylized circular icon composed of three overlapping, teardrop-shaped curves in dark blue, teal, and light gray, arranged in a spiral pattern.
On this page ▾

Key takeaways

  • An independent committee found no safety concerns in Sensorion’s gene therapy trial for deafness caused by a faulty OTOF gene.
  • Two of three children in the higher-dose group showed early hearing improvement at three months, sustained at six months.
  • In June 2026 Sensorion stopped developing SENS-501; in April 2026 the US approved a different OTOF gene therapy.
  • Hearing aids and cochlear implants remain the main options for many children with this type of deafness.
  • These are early results from very few children, so lasting benefit is not yet known.

In December 2025, Sensorion said an independent committee had found no safety concerns so far in its Phase 1/2 trial of SENS-501, an experimental gene therapy for babies and toddlers born deaf because of a faulty OTOF gene1. Update, June 2026: Sensorion has since stopped developing SENS-501 and ended recruitment to the trial, and says it will keep following up the children already treated3. Separately, in April 2026 the US Food and Drug Administration approved a different gene therapy for OTOF-related hearing loss, Regeneron’s Otarmeni4.

If you are the parent of a child with hearing loss, your child’s audiology team can explain which options apply to your family.

Sensorion is a French clinical-stage biotechnology company focused on treatments for hearing loss and balance disorders. The independent committee reviewed the first stages of the Audiogene Phase 1/2 trial and allowed the study to continue at the time1.

What was the trial testing?

The Audiogene trial was testing SENS-501, an experimental gene therapy for children born with deafness caused by a faulty OTOF gene. This gene is essential for passing sound signals from the inner ear hair cells to the auditory nerve.

Children were 6 to 31 months old when treated, and each child was treated in one ear.

What did the safety review find?

An independent data monitoring committee examined early data from the first two small groups of children in the study. The second group had three children. Sensorion said the committee found that the procedure was well tolerated and that no serious side effects were reported. Based on that review, the committee supported continuing the trial as planned.

Did hearing improve?

Sensorion has also shared early indications that the gene therapy may be having an effect. In the second group of three children, two showed early improvement on pure-tone hearing tests three months after treatment, and Sensorion later reported that the improvement was sustained at six months2. At their best frequency, their thresholds were about 60 and 70 dB HL, which is still a significant hearing loss.

The company stressed that these are early signals from very few children. More time and data are needed to understand whether the changes are lasting and meaningful in everyday listening.

Why does this matter?

For families affected by congenital deafness linked to the OTOF gene, current options are limited. Management options such as hearing aids or cochlear implants help many children, but they do not address the underlying cause.

SENS-501 aimed to treat the cause by giving the inner ear a working copy of the gene, so that sound signals can reach the auditory nerve. Whether it can do that safely and lastingly was still being tested. See also our articles on gene therapy for congenital deafness and newborn hearing screening.

Why caution remains

“Any research involving very young children quite rightly moves slowly,” said Jessica Tovey, a Clinical Audiologist at Hearology. “Seeing reassuring safety data is an important first step, but it will take time to know whether this kind of treatment can make a real difference for families.”

Share this article
For children aged 3 to 12

Whatever is troubling your child's ears, you're in good hands.

Gentle microsuction, and you're welcome to stay with your child throughout.

Book nowRead more
  • Same-day availability
  • Microsuction only

Frequently asked questions

Can gene therapy cure deafness?
Not in general. Gene therapy is being tested for rare inherited types of deafness, such as OTOF-related hearing loss, and one therapy has been approved in the US. Most deafness has other causes, so it will not apply to everyone.
What is OTOF hearing loss?
It is a rare inherited form of deafness in which a faulty OTOF gene stops sound signals passing from the inner ear hair cells to the hearing nerve. Babies are usually born with significant hearing loss, and genetic testing can confirm the cause.
What helps children born deaf today?
Hearing aids or cochlear implants help many children, along with support from an audiology team and early intervention. They do not change the underlying cause. If you have concerns about a child’s hearing, speak to your GP or health visitor.
How is a baby’s hearing checked?
All babies are offered a newborn hearing screen, usually before they are 4 weeks old, though it can be done up to 3 months. The test takes a few minutes and you get the result straight away. If your baby needs further tests, an audiology team will arrange them. Our article on newborn screening explains more.

References:

  1. [1] Sensorion, "Sensorion reports independent Data Monitoring Committee raises no safety concerns and agrees to continue SENS-501's Audiogene Phase 1/2 trial," Dec. 8, 2025. Accessed: Nov. 16, 2026. [Online]. Available:
  2. [2] Sensorion, "Sensorion reports six month update from the Audiogene Phase 1/2 trial of SENS-501 and advances GJB2 GT SENS-601 toward first-in-human," Mar. 23, 2026, republished by Sofinnova Partners. Accessed: Nov. 16, 2026. [Online]. Available:
  3. [3] Sensorion, "Sensorion achieves key regulatory milestones for SENS-601 in GJB2-related hearing loss," Jun. 10, 2026, republished by Sofinnova Partners. Accessed: Nov. 16, 2026. [Online]. Available:
  4. [4] U.S. Food and Drug Administration, "OTARMENI," Vaccines, Blood and Biologics. Accessed: Nov. 16, 2026. [Online]. Available:
From Hearology
Typographic ad reading: You didn't hear the punchline.
Hearing screeningA 30-minute hearing check at a Hearology clinic.Book a hearing screening
Author
Written by HearologyThe Hearology team
Keep reading

More in Research

ResearchStudy links ADHD listening difficulties to brain networks3 min read
ResearchDB-OTO gene therapy for inherited deafness: what the trial found3 min read
ResearchBrain-inspired tech could transform hearing in noisy places3 min read
More Research articles →